Focused on Patient-Centricity by Delivering Clinical Trials Directly to Patients

We understand how challenging it is to adopt a novel approach to drug development. Pivoting to virtual clinical trials is no exception.

The focus on delivering patient-centric practices to improve clinical trial participation by reducing the burden on patients is the cornerstone of clinical research excellence. Over the last few years, there has been a shift to bring the clinical trial to the patient’s home, an evident disruption of historical clinical trial conduct practices. While adoption has not been widespread, the COVID-19 pandemic has rapidly turned this ideology into a necessary reality.

The time for virtual trial adoption is now. A flexible virtual clinical trial approach is the solution.

Solving Challenges with a Virtual Clinical Trial Approach

The Veristat virtual clinical trial approach is both flexible and customizable to the needs of each patient and trial design.  For example, traditional on-site activities such as dosing, lab work, and follow-up can be conducted remotely at home or through a hybrid model that combines both on-site and at-home visits. In some cases, the investigational product (IP) may be shipped directly to the patient or brought to the patient by a traveling nurse. In other situations, nurses conduct at-home visits to dose patients. They also collect demographic information, vitals, and perform simple lab work. When needed, a patient might visit a local lab for more complex lab work. The investigator/doctor can conduct some visits with the patient through Telemedicine as well. The customizations are infinite.

The virtual trial model solves many significant challenges facing drug developers today:  

• Improving patient recruitment and retention for trials by reducing the patient burden of travel and time going to physical sites
• Finding the right patients by removing geographic barriers to patient eligibility
• Offering a flexible and fully integrated hybrid site model customized to the comfort levels of the patients, sites, sponsors, etc.
• Overcoming COVID-19 restrictions and restoring continuity of new and ongoing clinical trials regardless of future restrictions